Switzerland· 68952001
Omvoh 100 mg, solution injectable en stylo prérempli
A mirikizumab product containing mirikizumabum, registered in Switzerland by Eli Lilly (Suisse) SA and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Mirikizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AC24 (mirikizumab), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Mirikizumab · ATC L04AC24
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of mirikizumab costs, country by country.
Normalised to the WHO defined daily dose (7.1 mg), so markets compare like for like.
- Switzerland: $30.99 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Mirikizumab · price per daily dose (7.1 mg)
USD · FX 28 Sept 2026
- CH Switzerland$30.99
The record
At a glance
Swissmedic (Switzerland)- Active substance
- mirikizumabum
- Manufacturer
- Eli Lilly (Suisse) SA
- Country
- Switzerland (CH)
- ATC code
- L04AC24
- ATC class
- Mirikizumab
- Defined daily dose
- 7.1 mg, P
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806895200182 StkCHF 1241.25
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mirikizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandOmvohEli Lilly Nederland B.V.
- CzechiaOMVOHEli Lilly Nederland B.V., Utrecht
- United StatesOmvohEli Lilly and Company
- FinlandOmvohEli Lilly Nederland B.V.
- BelgiumOmvoh 100 mgEli Lilly Nederland
- SwedenOmvoh 100 mg + 200 mg Injektionsvätska, lösning i förfylld injektionspennaEli Lilly Nederland B.V.
- IrelandOmvoh 100 mg solution for injection in pre-filled syringeEli Lilly Nederland B.V.
- IcelandOmvohEli Lilly Nederland B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Omvoh
- Liechtenstein · Omvoh
- Norway · Omvoh
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ed112f26-3207-44b1-b531-07c41cfe1adb GET /v1/drugs/ed112f26-3207-44b1-b531-07c41cfe1adb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "mirikizumabum 100 mg",
"valid_from": "2026-02-01",
"limitations": "[{\"description\":\"<p><strong>Colitis Ulcerosa</strong><br>Die Verschreibung kann nur durch Fachärzte der Gastroenterologie oder gastroenterologische Universitätskliniken/Polikliniken erfolgen.<br>Erhaltungstherapie zur Behandlung erwachsener Patienten mit mittelschwerer bis schwerer aktiver Colitis ulcerosa, bei denen konventionelle Therapien oder die Behandlung mit einem Biologikum ungenügend angesprochen haben, nicht mehr ansprechen, kontraindiziert sind oder nicht vertragen wurden. <br>Es wird maximal eine Dosis von 200 mg pro Verabreichung alle 4 Wochen vergütet.<br>Eine Weiterbehandlung mit OMOVH nach einem Jahr bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>Es werden ausschliesslich die Packungen zu 100 mg/ml, 2 Fertigpen zu 1 ml oder 200 mg/2 ml, 1 Fertigpen zu 2 ml für die Erhaltungsphase in der Indikation Colitis Ulcerosa vergütet.<br>Der Indikationscode dieser Limitierung ist an den Krankenversicherer zu übermitteln.</p>\",\"costApproval\":null,\"indication\":\"21670.01\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-08-01\",\"validTo\":\"2026-09-30\"}]",
"galenic_form": "Inj Lös 100 mg/ml Fertpen",
"therapeutic_area": null,
"sl_inclusion_date": "2024-08-01",
"self_retention_pct": 10
}See everything about mirikizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.